Anticancer effect of long-circulating nanoliposome packaging paclitaxel in vitro and in vivo

TANG Yong,LI Jian,ZHANG Yang-de

DOI: https://doi.org/10.3969/j.issn.1005-8982.2012.10.006

2012-01-01

Abstract:【Objective】 To explore the anticancer effect of the long-circulating liposome packaging paclitaxel(PAC-LS) in vitro and in vivo.【Methods】 In vitro,the cytotoxicity of LS,paclitaxel(PAC) and the lipid of PAC(PAC-LS),was studied in PANC-1 pancreatic cancer cells with M'IT assay.In vivo the anticancer effect of PAC and PAC-LS was determined in the BALB/C mice bearing pancreatic carcinoma.PAC or PAC-LS with the dosage of 10 mg/kg was injected into the mice's through tail vein after the tumor size reached 8 mm in diameter(about 15 days later).Tumor size was measured three times a week,until the death of mice or 60 d.The time of the tumor volume increasing quintuples(t5v) and the survival period of the mice were evaluated.The tumor volume growth delay(TGD) time was calculated.【Results】 The lipid used in the preparation of PAC-LS was proved no cytotoxicity to PANC-1 cell line.The inhibitive rate of PAC-LS to PANC-1cell line was greater than that of PAC.The IC50 of PAC was almost two times of PAC-LS(3.38 mg/L vs 1.63 mg/L).In BALB/C mice bearing pancreatic carcinoma,the injection of PAC-LS resulted in longer tumor growth delay time than PAC [(13.65±2.3) vs(4.5±1.83)d,P <0.01].PAC-LS administration also prolonged the median survival of mice(44.7d vs 23.0 d,P <0.01).【Conclusion】 The long-circulating liposome packaging paclitaxel produces greater anticancer effect than paclitaxel both in vitro and in vivo experiments.